Dan Nandan is the CEO of Staffingly, Inc. With 25+ years in IT consulting and a decade leading healthcare BPO operations across India, Latin America, and Pakistan, his team now serves 800+ U.S. healthcare providers across medical, dental, pharmacy, and post-acute care verticals.
2026 Compliance Verified: HIPAA, SOC 2 Type II, ISO 27001, HITRUST-aligned workflows.
Featured in Computerworld →
Clinically Reviewed By
Clinical Content Reviewer. IL RN License #041.577729
State of Illinois. Registered Professional Nurse
Bincy Shiiju Kuriakose is a U.S.-licensed Registered Nurse (MSN, RN), NCLEX-RN certified, with expertise in hospital nursing, telehealth, and nursing education. She reviews every publication for medical accuracy, YMYL compliance, and evidence-based clinical context.
Definition
You Get Prior Authorization for Trulicity with Optum Rx Medicare: Quick Overview
- Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist injection for T2DM
- FDA-approved for blood glucose management and cardiovascular risk reduction in T2DM patients
- Classified as Tier 3 (preferred brand) on most Optum Rx Medicare Part D formularies
- PA required because GLP-1s are high-cost specialty drugs; payers want to confirm medical necessity and that first-line therapies (metformin) were tried
- Nearly 100% of GLP-1 scripts now require PA under Medicare Part D (Source: Medical Economics, 2025)
- Dulaglutide covered by 87.5% of Part D plans, but with PA/step therapy/quantity limits attached (Source: PMC/NIH)
Gather A1C + Metformin Trial
Code E11.9 Diagnosis
Optum Rx ePA Portal
Submit + ePA Key
Track 72h / 7-Day Decision
Appeal If Denied
Key Takeaways for Healthcare Leaders
~100%
Of GLP-1 scripts now require PA under Medicare Part D
72 hrs
Expedited PA decision window under CMS-0057-F (7 days
standard)
87.5%
Of Part D plans cover dulaglutide, often with PA/step therapy
90 days
Recency required for A1C labs and documented metformin trial
4 pens
Typical quantity limit per 28-day supply on Optum Rx
E11.9
Baseline ICD-10 code (T2DM without complications) for the PA
60 days
Window to file a formal appeal after a denial
T2DM only
Trulicity is FDA-approved for Type 2 Diabetes, not weight loss
Key Takeaways for Providers
- ICD-10 code E11.9 (T2DM without complications) is the baseline; also use E11.65 (T2DM with hyperglycemia) or E11.22 (T2DM with diabetic chronic kidney disease) when applicable
- Step therapy is common: Optum Rx may require documented metformin trial (90+ days) before approving Trulicity
- A1C lab results within the past 90 days are critical documentation
- Quantity limits typically cap at 4 pens (0.75mg or 1.5mg) per 28-day supply
- As of 2026, Optum Rx must respond within 72 hours (expedited) or 7 calendar days (standard) under CMS-0057-F
- Appeal window is 60 days from denial date; peer-to-peer review is available
Step-by-Step Trulicity PA Process with Optum Rx Medicare
Phase 1: Submission Setup
Step 1 — Access the Optum Rx ePA Portal
- Log into Optum Rx’s electronic prior authorization system at business.optum.com
- Retrieve the unique electronic key (ePA key) that tracks the request through Optum’s system
- Alternative: submit via CoverMyMeds or Surescripts if your EHR integrates with those platforms
Step 2 — Enter Patient Demographics
- Full legal name, DOB, address, Optum Rx Member ID
- Medicare Beneficiary Identifier (MBI) for Part D verification
- Confirm the patient’s Optum Rx plan is active and Trulicity is listed on the formulary (even if PA-required)
Step 3 — Enter Drug Details
- Drug: Trulicity (dulaglutide)
- NDC codes: varies by dose (0.75mg, 1.5mg, 3.0mg, 4.5mg auto-injectors)
- Quantity: typically 4 pens per 28-day supply
- Days supply: 28 days
- New start vs. continuation (renewal PAs may require updated labs)
Step 4 — Enter Prescriber Information
- NPI number, full name, DEA (if required), office address, phone, fax
- Optum Rx verifies the prescriber is a licensed provider authorized to prescribe GLP-1 injectables
Phase 2: Clinical Documentation
Step 5 — Attach Clinical Records
- A1C lab results (within 90 days, showing A1C above 7.0% or payer-specific threshold)
- Documentation of metformin trial (minimum 90 days) or documented contraindication/intolerance
- List of all current diabetes medications
- Provider notes explaining why Trulicity was selected over alternatives (cardiovascular benefit, renal protection, patient tolerance)
Step 6 — Enter Diagnosis Codes
- Primary: E11.9 (T2DM without complications)
- Secondary as applicable: E11.65 (T2DM with hyperglycemia), E11.22 (T2DM with diabetic CKD), I25.10 (atherosclerotic heart disease) for cardiovascular indication
- Accurate coding directly impacts approval likelihood
Step 7 — Submit and Track
- Review all fields, then submit electronically
- Save the confirmation number and ePA key
- Track status through the Optum Rx portal; expect decision within 72 hours (expedited) or 7 days (standard)
- If no response within the CMS-mandated timeframe, escalate by calling Optum Rx PA line at 1-800-711-4555
Optum Rx PA Policies and Formulary Rules for Trulicity
- Trulicity is typically Tier 3 (preferred brand) on Optum Rx Medicare Part D formularies, meaning PA + possible step therapy
- Step therapy requirement: most Optum Rx plans require a trial of metformin (or documented intolerance) before approving a GLP-1. When the metformin step does not fit the patient, a GLP-1 step therapy override request can be filed
- Some plans also require trial of a sulfonylurea or SGLT2 inhibitor before GLP-1 approval
- Quantity limits: 4 pens per 28-day fill; requests for higher quantities require additional justification
- Renewal PAs: patients on long-term Trulicity may need updated A1C results every 6-12 months to maintain authorization
- Comparison table: Trulicity vs. Ozempic vs. Mounjaro on Optum Rx formulary (tier, PA requirements, step therapy, quantity limits)
Comparison Table
*(Source: Optum Rx formulary documents 2025-2026; tier placement varies by specific plan)*
Cut healthcare outsourcing turnaround time
Save 40-70% with dedicated Healthcare specialists
Book a 15-minute call. We will map your current healthcare outsourcing workflow, denial rates, and staff hours against what a dedicated team typically delivers in the first 30 days.
HIPAA . SOC 2 Type II .
HITRUST-aligned . 800+ U.S. providers served
ICD-10 and Compliance Codes for Trulicity PA
- E11.9 — T2DM without complications (most common primary code)
- E11.65 — T2DM with hyperglycemia
- E11.22 — T2DM with diabetic chronic kidney disease
- E11.51 — T2DM with diabetic peripheral neuropathy
- I25.10 — Atherosclerotic heart disease (supports cardiovascular risk reduction indication)
- Z79.84 — Long-term (current) use of oral hypoglycemic drugs (documents metformin trial)
- HCPCS J3490 — Unclassified drugs (used if specific Trulicity HCPCS not assigned by plan)
- Accurate, specific coding reduces denial rates. Using E11.9 alone when the patient has complications is a common mistake that triggers denials.
What to Do If Trulicity PA Is Denied by Optum Rx
- Step 1: Request the denial letter within 24 hours. Read the exact denial reason (medical necessity not established, step therapy not met, missing documentation, etc.)
- Step 2: File a formal appeal within the 60-day window. Address each denial reason point by point.
- Step 3: Attach updated clinical evidence — new A1C results, specialist notes, peer-reviewed literature supporting Trulicity for the patient’s specific comorbidities
- Step 4: Request peer-to-peer review if the written appeal is denied. The prescribing physician speaks directly with the plan’s medical director. Reddit PA specialists report this overturns a significant portion of automated denials.
- Step 5: If all internal appeals fail, file an Independent Review Entity (IRE) appeal through Medicare. Medicare beneficiaries have the right to an external review.
- Timeframes under CMS-0057-F: Optum Rx must decide standard appeals within 7 calendar days, expedited appeals within 72 hours
- Pro tip from Reddit: Resubmitting a PA a second time (not an appeal, a fresh PA) with targeted documentation addressing the original denial reason often results in approval
State-Specific PA Considerations: FL, TX, OH
Florida:
- FL Medicaid MCOs (Sunshine Health, Molina, Humana) each have independent Trulicity PA criteria; no single state-wide formulary
- FL SB 1550 (2024) requires commercial insurers to respond to urgent prescription PAs within 48 hours
- FL has one of the highest Medicare Advantage enrollment rates in the country; most FL MA plans are administered by UnitedHealth/Optum, making Optum Rx PA rules especially relevant here
Texas:
- TX is one of 6 CMS PA pilot states in 2026 (for Medicare FFS procedures, not Part D drugs, but PA infrastructure is expanding)
- TX Medicaid (STAR/STAR+PLUS) covers Trulicity for T2DM but requires step therapy through metformin and A1C documentation above 7.0%
- TX has the second-highest uninsured rate nationally; for the Medicare population that does have coverage, PA efficiency is critical to avoid treatment gaps
Ohio:
- OH is also a CMS PA pilot state in 2026
- OH Medicaid (CareSource, Buckeye, Molina) includes Trulicity on preferred drug lists with PA + documented metformin failure or contraindication
- OH HB 122 (2024) caps PA response times at 48 hours (urgent) and 5 business days (standard) for commercial plans
Why Practices Outsource Trulicity PA to Staffingly
*(Replaces original “Conclusion” — CTA-focused, addresses “Trulicity diabetes PA outsourcing” keyword)*
- The average PA takes 25-35 minutes of staff time per request. For a practice prescribing GLP-1s to 50+ patients/month, that is 20+ hours/month on PA alone.
- Staffingly’s trained PA specialists handle Trulicity prior authorization and other GLP-1 PAs end to end: submission, tracking, denial follow-up, appeals, peer-to-peer coordination
- For payer-specific work, our Optum prior authorization team knows Optum Rx ePA criteria, documentation thresholds, and escalation paths
- 99.2% clean claim rate across 800+ providers
- Starting at $399/week (volume discounts to $299/week), 70% less than in-house staff costs
- 48-72 hour go-live; integrates with 50+ EHR platforms including eCW, Athena, NextGen
- SOC 2 Type II, HITRUST, ISO 27001, HIPAA compliant
- 15-Day Risk-Free Pilot available (no long-term contract required)
CTA Angle
Problem we solve: GLP-1 prior authorizations eat 20+ staff hours per month at practices with 50+ diabetes patients. Denials, step therapy requirements, and appeal cycles compound the burden. Providers need trained PA specialists who know Optum Rx’s specific criteria, documentation thresholds, and appeal procedures.
Staffingly pitch: Trained PA specialists who handle Trulicity, Ozempic, Mounjaro, and all GLP-1 PAs end to end. 99.2% clean claim rate. $399/week (volume discounts to $299/week). 15-Day Risk-Free Pilot.
Key Sources
- Medical Economics 2025: medicaleconomics.com/view/medicare-beneficiaries-face-higher-costs-near-universal-prior-authorization-for-glp-1-drugs
- PMC/NIH GLP-1 Coverage Study: pmc.ncbi.nlm.nih.gov/articles/PMC12397888/
- CMS GLP-1 Bridge: cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- CMS CY2026 Final Rule (CMS-4208-F): cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes…
- Optum Rx ePA portal: business.optum.com/en/pharmacy-services/electronic-prior-authorization.html
- DevelopHealth.ai ePA stats: develophealth.ai/blog/ai-prior-authorization
Frequently Asked Questions
A: Trulicity is a high-cost GLP-1 injectable. Optum Rx
requires PA to confirm medical necessity and verify that
first-line therapies like metformin have been tried or are
contraindicated. Nearly 100% of GLP-1 prescriptions under
Medicare Part D now require PA.
A: Under CMS-0057-F (effective January 2026), Optum Rx must
respond within 72 hours for expedited requests and 7 calendar
days for standard requests. Previously, response times could
stretch to 14+ days.
A: You have 60 days to file a formal appeal. Address each
denial reason specifically, attach updated clinical
documentation, and request a peer-to-peer review if the
written appeal fails. Medicare beneficiaries also have the
right to file an external appeal through an Independent Review
Entity (IRE).
A: A1C lab results within 90 days, documentation of metformin
trial (90+ days) or contraindication, list of current diabetes
medications, and prescriber notes explaining why Trulicity was
selected. ICD-10 code E11.9 is the baseline, with additional
codes as clinically appropriate.
A: No. Trulicity is FDA-approved only for Type 2 Diabetes
management. Medicare Part D covers Trulicity for T2DM. For
weight-loss GLP-1 coverage, the CMS Medicare GLP-1 Bridge
(July-December 2026) covers drugs such as Wegovy and Zepbound,
but not Trulicity.
A: Trulicity (dulaglutide) is covered by approximately 87.5%
of Medicare Part D plans and typically sits at Tier 3
(preferred brand) on Optum Rx formularies. However, tier
placement and PA requirements vary by specific plan.
A: Yes. Practices handling high volumes of GLP-1 PAs outsource
to dedicated PA teams like Staffingly, which handles
end-to-end submission, tracking, denials, and appeals starting
at $399/week (volume discounts to $299/week) with a 15-Day
Risk-Free Pilot.
